Fundz

Tracon Pharmaceuticals Announces Up To $30M Non-Recourse Non-Dilutive Financing Related To Arbitration Award Decision Expected In Q1 2023

PRIVATEDec 27, 2022

Amount Raised

$30 Million

Round Type

Grant

San DiegoBiotechnologyHealth CarePharmaceutical

Description

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced entry into an up to $30 million non-recourse financing agreement.

Who else raised in Pharmaceutical and Biotechnology around the same time

Companies in the same sectors as TRACON that raised within 45 days of this round, from Fundz verified event records.

  • CUREMARK LLC raised $1.3M (Seed) on January 30, 2023.
  • Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
  • Liquidia raised an undisclosed amount (Debt Financing) on January 9, 2023.
  • HighTide Therapeutics raised $107M (Series C) on January 5, 2023.
  • Madrigal Pharmaceuticals raised $300M (Funding Round) on December 21, 2022.
  • ExPLoRNA Therapeutics raised an undisclosed amount (Funding Round) on December 7, 2022.

Who to call at TRACON, and when

A new round usually means TRACON is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TRACON raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TRACON, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TRACON. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TRACON

Location

La Jolla Village Drive

San Diego, California, United States

About

TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TRACON raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for TRACON's next move

See what Strategic adds

TRACON raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.